You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Oct 30, 2026; less than a full year is stored.
Aspen Neuroscience, Inc. completed its IPO on November 2, 2026, selling 9,375,000 common shares at $15.00 per share and generating approximately $140.6 million in gross proceeds before underwriting discounts, commissions and offering expenses. Its amended certificate and bylaws became effective.
Aspen Neuroscience, Inc. proposes an initial public offering of 9,375,000 common shares at $15.00 to $17.00 per share and plans to list under “ASPE” on Nasdaq Global Select Market. Its sasineprocel ASPIRO trial had dosed 15 patients by August 18, 2026.
Aspen Neuroscience, Inc. proposes an initial public offering of common stock and plans to list on Nasdaq under “ASPE”; in the Phase 1/2a ASPIRO trial, 15 patients had been dosed as of August 18, 2026, with sasineprocel generally well-tolerated.
Aspen Neuroscience, Inc. is pursuing an initial public offering of common stock and plans to list it on Nasdaq Global Select Market under “ASPE.” Its lead candidate, sasineprocel, is being evaluated for Parkinson’s disease, with 15 patients dosed.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASPE
this stock
Aspen Neuroscience, Inc.
|
$395.76M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Aspen Neuroscience, Inc. completed its IPO on November 2, 2026, selling 9,375,000 common shares at $15.00 per share and generating approximately $140.6 million in gross proceeds before underwriting discounts, commissions and offering expenses. Its amended certificate and bylaws became effective.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASPE | +15.7% | — | — | -8.6% | — |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | +12.4% | — | — | -8.8% | — |
